

4 December 2024

ASX Compliance
Reference: 104072

By email: ListingsComplianceSydney@asx.com.au

Syntara Limited ('SNT'): Price – Query

We refer to ASX's letter dated 3 December 2024 and respond as follows:

1. *Is SNT aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?*

Yes.

If the answer to question 1 is "yes".

(a) Is SNT relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in SNT's securities would suggest to ASX that such information may have ceased to be confidential and therefore SNT may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.

(b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).

(c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?

As noted in SNT's ASX announcement of 6 November 2024, SNT is making an oral presentation at the American Society of Hematology meeting (**ASH Meeting**) scheduled for 5.30pm US Pacific Time on 9 December 2024 (12.30pm on 10 December 2024, Sydney time). Interim data (**Interim Data**) from SNT's Phase 2 trial evaluating SNT-5055, in combination with ruxolitinib to treat the bone marrow cancer myelofibrosis, will be presented at the ASH Meeting after completing a peer review process with leading hematologists shortly prior to SNT's presentation at the ASH Meeting. Previous ASX announcements by SNT (including in its September Quarterly Shareholder Update) have also flagged the plan to release the Interim Data in December 2024.

It should be noted that patients participate in this trial for 12 months. The first patient commenced in December 2023 and the last patient commenced in August 2024. No patients in the Interim Data have yet completed 12 months of treatment. The trial will therefore not complete until August 2025 and the complete data is only expected in H2 2025. Accordingly, SNT will not know the final outcome of the trial until after that time. While the presentation at the ASH Meeting will provide

an update relating to patients at various stages of the trial, the final data may vary from the Interim Data. Moreover, the trial is not sufficiently advanced to have generated enough data for SNT to approach the FDA on the study design for a pivotal trial – the next milestone in development of the drug.

The Interim Data is currently only known to a limited number of people on a confidential basis. SNT has no reason to believe that any of the Interim Data has ceased to be confidential.

The Interim Data is confidential, uncertain and requires peer review prior to presentation, and is therefore insufficiently definite to warrant disclosure. A reasonable person would not expect the information to be disclosed. The Interim Data therefore falls within the carve-out from disclosure in Listing Rule 3.1A. However, because it is intended that the Interim Data be presented for scientific purposes at the ASH Meeting and would cease to be confidential at that time, SNT will first make an ASX announcement.

SNT is confident that the Interim Data remains confidential and therefore the information in the Interim Data is **not** the reason for the recent trading in its securities. The recent trading activity could be the result of anticipation by certain investors of the release of the Interim Data at the ASH Meeting. However, as noted above, the Interim Data may vary from the final outcome of the trial and is not a definitive indication of the final results. Additionally, SNT considers that recent trading activity could have been impacted by the initiation of coverage by a major broker on 2 December 2024 and increased investor relations activities by SNT over recent months.

As noted above, prior to presentation of the Interim Data, because of the stage and nature of the trial, peer review by leading hematologists of the data is considered essential. That review process will only complete shortly before SNT's presentation at the ASH Meeting, and release of the data prior to completion of this process would be premature. SNT intends to release an ASX announcement detailing the Interim Data immediately before its presentation.

2. If the answer to question 1 is "no", is there any other explanation that SNT may have for the recent trading in its securities?

As noted in response to question 1 above, the recent trading activity could be the result of anticipation by certain investors of the release of the Interim Data at the ASH Meeting. Recent trading activity could also have been impacted by the initiation of coverage by a major broker on 2 December 2024 and increased investor relations activities by the company over recent months.


3. Please confirm that SNT is complying with the Listing Rules and, in particular, Listing Rule 3.1.

SNT confirms that it is in compliance with the Listing Rules and in particular, Listing Rule 3.1.

4. *Please confirm that SNT's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of SNT with delegated authority from the board to respond to ASX on disclosure matters.*

Confirmed.

Yours faithfully
Syntara Limited

A handwritten signature in black ink, appearing to read 'D. McGarvey', with a large, sweeping flourish underneath.

David McGarvey
Company Secretary



3 December 2024

Reference: 104072

Mr David McGarvey
Company Secretary
Syntara Limited

By email:

Dear Mr McGarvey

Syntara Limited ('SNT'): Price - Query

ASX refers to the following:

- A. The change in the price of SNT's securities from a low of \$0.048 to a high of \$0.069 in the last few days.
- B. The significant increase in the volume of SNT's securities traded from 29 November 2024 to 3 December 2024.

Request for information

In light of this, ASX asks SNT to respond separately to each of the following questions and requests for information:

- 1. Is SNT aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?

If the answer to question 1 is "yes".

- (a) Is SNT relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in SNT's securities would suggest to ASX that such information may have ceased to be confidential and therefore SNT may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
 - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
 - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
- 2. If the answer to question 1 is "no", is there any other explanation that SNT may have for the recent trading in its securities?
 - 3. Please confirm that SNT is complying with the Listing Rules and, in particular, Listing Rule 3.1.
 - 4. Please confirm that SNT's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of SNT with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **9.30 AM AEDT Wednesday, 4 December 2024**. You should note that if the

information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, SNT's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require SNT to request a trading halt immediately.

Your response should be sent to me by e-mail at **ListingsComplianceSydney@asx.com.au**. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in SNT's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in SNT's securities under Listing Rule 17.3.

Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to SNT's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that SNT's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Release of correspondence between ASX and entity

ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

Kind regards

ASX Compliance